Lonza Group Ltd LZAGY
Morningstar’s Analysis
1-Star Price
PREMIUM
5-Star Price
PREMIUM
Economic Moat
PREMIUM
There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible for overseeing the methodology that supports the quantitative fair value. As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.'s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities. For information regarding Conflicts of Interests, click here .
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile
Lonza Group is a contract development and manufacturing organization. It also produces microbicides and other chemicals for personal care, health and hygiene, agrochemical, and industrial preservation markets. The firm is organized into two segments: Pharma Biotech and Nutrition, which encompasses drug development and manufacturing as well as consumer health manufacturing, and Specialty Ingredients, which encompasses businesses in industrials, consumer care, and agriculture. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic and government research organizations, and consumer goods and industrial companies.
Basel, 4002, Switzerland